Metastatic melanomas of unknown primary show better prognosis than those of known primary: A systematic review and meta-analysis of observational studies

被引:65
作者
Bae, Jung Min [1 ,2 ,3 ]
Choi, Yoon Young [4 ]
Kim, Dae Suk [2 ,3 ]
Lee, Ji Hye [3 ,5 ]
Jang, Hong Sun [2 ,3 ]
Lee, Joo Hee [1 ]
Kim, Heesu [2 ,3 ,7 ]
Oh, Byung Ho [2 ,3 ]
Roh, Mi Ryung [3 ,5 ]
Nam, Kyoung Ae [2 ]
Chung, Kee Yang [2 ,3 ,6 ]
机构
[1] Catholic Univ Korea, St Vincents Hosp, Dept Dermatol, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Dermatol, Seoul 120752, South Korea
[3] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea
[4] Yonsei Univ, Coll Med, Severance Hosp, Cutaneous Biol Res Inst, Seoul 120752, South Korea
[5] Yonsei Univ, Coll Med, Dept Dermatol, Gangnam Severance Hosp, Seoul 120752, South Korea
[6] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea
[7] Catholic Kwandong Univ, Coll Med, Int St Marys Hosp, Dept Dermatol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
malignant melanoma; melanoma; unknown primary; meta-analysis; prognosis; systematic review; THIN MALIGNANT-MELANOMA; LYMPH-NODES; PRIMARY ORIGIN; IMPROVED SURVIVAL; PRIMARY SITE; VITILIGO; LESION; END;
D O I
10.1016/j.jaad.2014.09.029
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Melanoma of unknown primary (MUP) is a condition of metastatic melanoma without a primary lesion. Objective: We sought to identify the prognosis of MUP compared with melanoma of known primary (MKP). Methods: We searched for observational studies containing at least 10 patients with MUP from MEDLINE and EMBASE from inception to December 22, 2012. The outcomes of interest were overall and disease-free survival; meta-analyses of hazard ratio stratified by stage using a random effects model were performed. In addition, second systematic review identified risk factors influencing the survival of patients with MUP. Results: Eighteen studies including 2084 patients with MUP and 5894 with MKP were included. MUP had a better overall survival compared with MKP in stage III (15 studies; hazard ratio 0.83, 95% confidence interval 0.73-0.96, P = .010) and stage IV (6 studies; hazard ratio 0.85, 95% confidence interval 0.75-0.96, P = .008). Secondly, 22 studies including 3312 patients with MUP were reviewed, and increased stage and old age were the risk factors in patients with MUP. Limitations: Diverse observational studies were reviewed, and selection and reporting biases are possible. Conclusions: The current meta-analyses suggest better survival outcomes in patients with MUP than those in patients with MKP with the same corresponding tumor stage.
引用
收藏
页码:59 / 70
页数:12
相关论文
共 59 条
[1]  
Anbari KK, 1997, CANCER-AM CANCER SOC, V79, P1816, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1816::AID-CNCR26>3.0.CO
[2]  
2-#
[3]  
[Anonymous], FITZPATRICKS DEMATOL
[4]   Final Version of 2009 AJCC Melanoma Staging and Classification [J].
Balch, Charles M. ;
Gershenwald, Jeffrey E. ;
Soong, Seng-jaw ;
Thompson, John F. ;
Atkins, Michael B. ;
Byrd, David R. ;
Buzaid, Antonio C. ;
Cochran, Alistair J. ;
Coit, Daniel G. ;
Ding, Shouluan ;
Eggermont, Alexander M. ;
Flaherty, Keith T. ;
Gimotty, Phyllis A. ;
Kirkwood, John M. ;
McMasters, Kelly M. ;
Mihm, Martin C., Jr. ;
Morton, Donald L. ;
Ross, Merrick I. ;
Sober, Arthur J. ;
Sondak, Vernon K. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206
[5]   A MULTIFACTORIAL ANALYSIS OF MELANOMA .3. PROGNOSTIC FACTORS IN MELANOMA PATIENTS WITH LYMPH-NODE METASTASES (STAGE-II) [J].
BALCH, CM ;
SOONG, SJ ;
MURAD, TM ;
INGALLS, AL ;
MADDOX, WA .
ANNALS OF SURGERY, 1981, 193 (03) :377-388
[6]   Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma [J].
Boasberg, Peter D. ;
Hoon, Dave S. B. ;
Piro, Lawrence D. ;
Martin, Maureen A. ;
Fujimoto, Akhide ;
Kristedja, Timothy S. ;
Bhachu, Sandeep ;
Ye, Xing ;
Deck, Regina R. ;
O'Day, Steven J. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (12) :2658-2663
[7]  
Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO
[8]  
2-G
[9]  
CHANG P, 1982, CANCER-AM CANCER SOC, V49, P1106, DOI 10.1002/1097-0142(19820315)49:6<1106::AID-CNCR2820490607>3.0.CO
[10]  
2-0